핵심요약

• NVIDIA의 앞으로의 수익 배수는 약 21배
• 1조 달러 파이프라인이 주가 상승에 기여하지 못함
• 2030년, 2040년의 장기적인 생물학적 혁신에 초점을 맞추는 것이 중요
• 단기적인 GPU 수요보다 장기적인 생명과학 시장의 잠재력이 더 중요

도입

이 기사는 NVIDIA의 전통적인 반도체 주기 평가 프레임워크를 넘어, 생명과학 분야의 잠재적 가치에 초점을 맞추고 있습니다. 투자자들은 단기적인 수익과 주가 변동성보다, 장기적인 생물학적 혁신이 가져올 수 있는 가치 창출 가능성에 주목해야 합니다.

본문 1: 생명과학 시장의 잠재적 가치

NVIDIA의 앞으로의 수익 배수가 약 21배인 것은 전통적인 반도체 주기 평가 기준으로 볼 때 합리적인 수준입니다. 그러나 기사는 이 배수를 넘어 생명과학 분야의 잠재적 가치를 고려할 것을 제안합니다. 생명과학 분야의 혁신은 단순한 GPU 출하량이나 데이터센터 확장과 같은 단기적인 요소를 넘어, 장기적인 가치 창출 가능성을 가지고 있습니다. 이는 NVIDIA의 주가 상승을 이끌 새로운 성장 동력이 될 수 있습니다.

본문 2: 단기적인 주가 반응의 한계

현재 NVIDIA의 1조 달러 파이프라인이 주가 상승에 기여하지 못하고 있는 점은 주목할 만합니다. 이는 투자자들이 단기적인 수익과 주가 변동성보다, 장기적인 생물학적 혁신이 가져올 수 있는 가치 창출 가능성에 주목해야 함을 시사합니다. 단기적인 주가 반응의 한계를 넘어, 장기적인 성장 가능성을 고려하는 것이 중요합니다.

결론

NVIDIA의 잠재적 가치는 전통적인 반도체 주기 평가 프레임워크를 넘어, 생명과학 분야의 혁신이 가져올 수 있는 장기적인 가치 창출 가능성에 있습니다. 투자자들은 단기적인 수익과 주가 변동성보다, 장기적인 생물학적 혁신이 가져올 수 있는 가치 창출 가능성에 주목해야 합니다. 향후 생명과학 분야의 기술 발전과 시장 동향을 지속적으로 모니터링하는 것이 중요합니다.

---

원문 링크: https://www.trefis.com/articles/594390/nvidias-secret-metric/2026-03-23?.tsrc=rss

Nvidia’s Secret Metric

Nvidia’s (NVDA) most important metric isn’t its data center revenue, hyperscaler capex trends, or the yield on its latest GPU chips.

It isn’t talked about much by semiconductor analysts and is mostly hidden behind dense tech jargon, but it may become one of the most important drivers of Nvidia’s stock – and could be the key to unlocking trillions in additional valuation over the next decade.

This analysis focuses on this underappreciated metric: The Total Addressable Market of Life.

Currently, the market is pricing Nvidia as a high-performing hardware leader. At roughly 21x forward earnings, the stock is arguably fairly valued if you view it through the lens of a traditional semiconductor cycle. But there lies the mistake: looking at Nvidia through the same prism as AMD or Intel only captures the “GPU cycle.” It does not yet account for the massive upside of a potential “Biology Premium.”

That disconnect is already showing up in how investors are reacting to near-term signals – Nvidia’s $1 trillion pipeline has barely moved the stock, even as several Nvidia vendors and customers look set to rally .

Nvidia and its most forward-looking investors are NOT focused on enterprise IT budgets. CEO Jensen Huang, the master entrepreneur, has been able to focus the world on an entirely different plane of existence. It’s good. No, it’s phenomenal—we all need to look beyond our noses. Look beyond chatbots and code generators to 2030 and 2040.

The message is simple. Gosh, how short-sighted can you be – look way far out into the future and imagine the human suffering we can eradicate. Disease is bad, cellular aging is terrible, and you don’t want your loved ones to suffer from incurable conditions. How dare you look and plan for the next quarter’s GPU shipments or even the next couple of years of data center buildouts? How short-sighted. Look at the fundamental nature of human biology and plan for the next century.

Look beyond chatbots and code generators to 2030 and 2040. Look at the fundamental nature of human biology and plan for the next century.

So what does that have to do with Nvidia stock?

How AI Compute Changes Biology

We may be witnessing the end of the so-called ‘Eroom’s Law’ (Moore’s spelled backwards) – the decades-long trend of drug discovery becoming slower and more expensive despite better technology. Biology is increasingly being treated as a computing problem because, at its core, it is a code-based system. By moving from slow, trial-and-error lab work to fast computer simulations using its powerful chips, Nvidia could help shrink drug discovery timelines from years to something much faster, closer to how software is built.

Here is how Nvidia might be executing this magic trick right under our noses.

1. The Digital Biology Narrative

Huang has publicly and repeatedly stated, including Precision Medicine World Conference 2025, that the next revolution won’t just be AI, but digital biology. He has explicitly redefined biology from a chaotic, unpredictable, trial-and-error science into a structured engineering discipline with a solvable “language.” The market could eventually value Nvidia not as a hardware vendor, but perhaps as a compiler of sorts for biology. This shift could move Nvidia from a cyclical hardware valuation to a high-multiple “deep tech” platform with more predictable, long-term software-like margins.

Nvidia isn’t likely to be just selling generic chips to scientists; they built an open development platform / software framework for life sciences called “BioNeMo.” By partnering with lab equipment titans like Thermo Fisher, they are closing the loop between digital AI simulation and physical robotic lab synthesis. Nvidia is positioning itself to own the pipeline from digital hypothesis to physical cure. By embedding their software into the physical laboratory infrastructure, Nvidia could create high switching costs and potentially capture a recurring slice of all R&D spending.

3. Powering the Protein Revolution

Proteins run everything in the body, and their function depends on their 3D shape. Figuring out those shapes used to take years of trial-and-error, making drug discovery slow and expensive. Projects like AlphaFold changed that by predicting structures at scale, and Nvidia is helping accelerate accelerates inference and downstream use of AlphaFold by supplying the massive compute. The data itself remains open, but Nvidia is building the high-speed infrastructure and tools, like BioNeMo, that make searching and simulating protein interactions far faster. That’s the real edge: turning biology from lab work into computation. If drug discovery becomes a simulation problem, Nvidia isn’t owning the biology; it’s powering the system that every company will need to use.

Nvidia understands that compute is only as valuable as the data it runs on. That’s why it made a $50 million PIPE investment in Recursion Pharmaceuticals, a biotech firm with a massive proprietary biological and chemical dataset exceeding 23 petabytes. Rather than owning that data, Nvidia is partnering to power Recursion’s discovery workflows using its DGX systems and AI platforms. The relationship is strategic: Recursion gets accelerated drug discovery, while Nvidia deepens its foothold in data-intensive biology. It’s not about exclusive control or building “master models” but about embedding its compute into high-value scientific pipelines. That still matters, positioning Nvidia closer to where cutting-edge biological data is generated and used.

5. Embedding in Big Pharma Workflows

Nvidia is embedding itself into the R&D pipelines of major pharma players like Novo Nordisk, which is using BioNeMo, NIM, NeMo, and Nvidia-powered supercomputing to accelerate AI-driven drug discovery. The bigger shift is subtler. Nvidia isn’t owning the drugs or their intellectual property, nor is there evidence it will take any royalties on resulting blockbusters. Instead, it’s positioning its platforms as core infrastructure inside early research workflows. That still creates leverage over time, not by turning pharma into manufacturers, but by becoming deeply embedded in how modern drug discovery gets done. Computational biology and the broader deployment of AI agents could drive up demand for AI inference chips. Here is how Nvidia is looking to outmaneuver Google and Amazon in this space.

Comparing Nvidia’s GPU sales to traditional chipmakers doesn’t fully explain the stock’s premium. Drug discovery operates on decade-long timelines. The relevant horizon is closer to 2035 than the next few years. If Nvidia becomes core infrastructure for computational biology, it participates in how drugs are discovered. Applied to a $1.5 trillion pharmaceutical market with high failure rates and inefficient R&D, the upside begins to reflect software-like economics.

If biology becomes a compute-driven process, the provider of that compute sits at a central point in value creation. Improvements in simulation speed and accuracy can scale across the entire system. If Nvidia cracks the simulation barrier, we could see an Alzheimer’s cure – not in 2040, but perhaps in the next, say, 5 to 7 years. Millions of families spared the slow horror of watching a loved one disappear. Trillions in healthcare costs vaporized. Entire economies reborn as productive longevity explodes.

Biology is slow, regulated, and uncertain. Progress can be uneven. But incremental gains in discovery timelines can compound across the healthcare system. The key variable is time horizon. Nvidia is building for a longer cycle than most investors model. Viewed through that lens, the valuation aligns more closely with long-term infrastructure rather than near-term hardware cycles.

The irony is this: the same long-term thinking Jensen Huang demands of the market applies to how you invest. Betting everything on a single stock, even one positioned at the intersection of AI and biology, carries real concentration risk over a decade-long horizon. If you want to stay invested through the volatility that comes with transformative, slow-moving bets like this one, a diversified approach matters. The High Quality Portfolio is built for exactly that – capturing upside in high-conviction themes while smoothing out the single-stock risk that comes with any one name, however compelling.

Source: https://www.trefis.com/articles/594390/nvidias-secret-metric/2026-03-23?.tsrc=rss